天康生物
(002100)
| 流通市值：87.10亿 | | | 总市值：87.10亿 |
| 流通股本：13.65亿 | | | 总股本：13.65亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 13,087,153,128.58 | 7,993,043,517.91 | 3,776,851,559.41 | 19,025,806,286.59 |
| 营业收入 | 13,087,153,128.58 | 7,993,043,517.91 | 3,776,851,559.41 | 19,025,806,286.59 |
| 二、营业总成本 | 12,617,293,868.82 | 7,789,522,484.27 | 3,678,286,988.75 | 19,995,177,780.14 |
| 营业成本 | 11,518,612,004.77 | 7,074,450,248.55 | 3,309,034,521 | 18,469,448,818.72 |
| 税金及附加 | 33,021,523.2 | 21,706,298.76 | 10,091,810.97 | 46,798,758.44 |
| 销售费用 | 353,352,827.23 | 233,330,190.16 | 129,381,097.22 | 543,057,284.05 |
| 管理费用 | 345,479,562.81 | 223,811,636.83 | 121,771,424.11 | 486,689,243.15 |
| 研发费用 | 249,626,186.54 | 154,290,133.74 | 66,463,953.07 | 257,231,957.14 |
| 财务费用 | 117,201,764.27 | 81,933,976.23 | 41,544,182.38 | 191,951,718.64 |
| 其中:利息费用 | 137,878,753.27 | 95,463,022.93 | 46,516,782 | 245,538,688.85 |
| 其中:利息收入 | 28,568,918.16 | 19,724,310.43 | 7,987,156.87 | 57,478,828.23 |
| 加:公允价值变动收益 | 72,374.02 | 48,766.16 | -448.68 | -3,530.44 |
| 加:投资收益 | -213,767.38 | -1,149,498.28 | 1,098,553.29 | 3,459,929.48 |
| 资产处置收益 | 2,266,143.89 | 878,022.72 | 0 | 3,898,306.2 |
| 资产减值损失(新) | 95,718,626.13 | 96,341,988.33 | -1,061,930.7 | -500,193,049.85 |
| 信用减值损失(新) | -29,898,067.63 | -16,973,222.79 | -19,011,981.18 | -53,203,203.11 |
| 其他收益 | 49,596,015.55 | 34,676,656.18 | 10,963,408.01 | 69,375,420.62 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 587,400,584.34 | 317,343,745.96 | 90,552,171.4 | -1,446,037,620.65 |
| 加:营业外收入 | 18,700,553.23 | 694,084.89 | 322,058.52 | 2,757,432.38 |
| 减:营业外支出 | 34,113,120.11 | 24,240,518.8 | 12,973,862.25 | 49,687,990.13 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 571,988,017.46 | 293,797,312.05 | 77,900,367.67 | -1,492,968,178.4 |
| 减:所得税费用 | 17,492,247.88 | 14,031,521.47 | 17,724,158.5 | 23,459,155.92 |
| 六、净利润 | 554,495,769.58 | 279,765,790.58 | 60,176,209.17 | -1,516,427,334.32 |
| 持续经营净利润 | 554,495,769.58 | 279,765,790.58 | 60,176,209.17 | -1,516,427,334.32 |
| 归属于母公司股东的净利润 | 565,624,390.53 | 276,682,923.94 | 54,063,760.85 | -1,363,316,030.34 |
| 少数股东损益 | -11,128,620.95 | 3,082,866.64 | 6,112,448.32 | -153,111,303.98 |
| (一)基本每股收益 | 0.41 | 0.2 | 0.04 | -1.01 |
| (二)稀释每股收益 | 0.41 | 0.2 | 0.04 | -1.01 |
| 八、其他综合收益 | 3,086,398.37 | -40,712,722.89 | -52,610,170.58 | 49,694,692.88 |
| 归属于母公司股东的其他综合收益 | 3,877,421.26 | -40,833,921.2 | -52,610,170.58 | 49,694,692.88 |
| 九、综合收益总额 | 557,582,167.95 | 239,053,067.69 | 7,566,038.59 | -1,466,732,641.44 |
| 归属于母公司股东的综合收益总额 | 569,501,811.79 | 235,849,002.74 | 1,453,590.27 | -1,313,621,337.46 |
| 归属于少数股东的综合收益总额 | -11,919,643.84 | 3,204,064.95 | 6,112,448.32 | -153,111,303.98 |
| 公告日期 | 2024-10-29 | 2024-08-29 | 2024-04-30 | 2024-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |